Form 4: Neurocrine Biosciences Director Lyons Acquires Stock Options and Restricted Stock Units

Director Gary A. Lyons acquired stock options and restricted stock units in Neurocrine Biosciences Inc. on May 22, 2024.

Summary

• On May 22, 2024, Gary A. Lyons, a director of Neurocrine Biosciences Inc., acquired 2,982 non-qualified stock options at a price of $0 and an exercise price of $139.43.
• Lyons also acquired 1,435 restricted stock units (RSUs) which represent the right to receive one share of Neurocrine Biosciences' common stock upon vesting.
• The RSUs will vest in full on May 22, 2025.
• The stock options vest in 12 monthly installments beginning June 22, 2024, and expire on May 22, 2034.
• Following these transactions, Lyons directly owns 2,982 stock options and 1,435 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares by a director could be seen as a positive signal, but it's not definitive.

Positives

• The acquisition of stock options and RSUs by a director may signal confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders such as directors and officers trade in their company's stock. These filings provide transparency to the market.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates